Tislelizumab
BeiGene
[]
phase 3 rationale 305 results presented at #gi23: a new 1l tx for pd-l1+ unresectable adv gastric/gastroesophageal junction adenocarcinoma? data shows tislelizumab + chemo brings improved survival vs placebo + chemo, with acceptable safety. more data to come from #noeticinsight! 